Doxazosin Dosing
For benign prostatic hyperplasia (BPH), start doxazosin at 1 mg once daily and titrate upward at 1-2 week intervals to a maximum of 8 mg daily; for hypertension, start at 1 mg once daily and titrate up to 16 mg daily as needed, but doxazosin should NOT be used as first-line monotherapy for hypertension due to increased heart failure risk. 1
Dosing for Benign Prostatic Hyperplasia
Starting dose: 1 mg once daily (morning or evening) 1
Titration schedule:
- Increase at 1-2 week intervals based on symptom response and tolerability
- Progression: 1 mg → 2 mg → 4 mg → 8 mg once daily
- Maximum dose: 8 mg once daily 1
- Evidence shows efficacy is dose-dependent—higher doses produce greater symptom improvement 2
Expected outcomes: Doxazosin produces a 4-6 point improvement in AUA Symptom Index, which patients perceive as meaningful change 2. Long-term studies demonstrate sustained efficacy with mean doses of 4 mg in normotensive and 6.4 mg in hypertensive BPH patients 3.
Dosing for Hypertension
Critical caveat: Doxazosin is NOT recommended as first-line therapy for hypertension. The 2020 ISH guidelines position doxazosin only as a 5th-line agent when spironolactone is not tolerated or contraindicated 4. This is because doxazosin monotherapy was associated with higher incidence of congestive heart failure compared to other antihypertensives 2.
If used for resistant hypertension:
- Starting dose: 1 mg once daily 1
- Titration: May double the dose as needed
- Maximum dose: 16 mg once daily 1
Special Populations and Clinical Scenarios
BPH Patients with Concomitant Hypertension
Important distinction: Using an alpha-blocker for BPH should NOT be assumed to constitute optimal management of concomitant hypertension 2. These patients may require separate antihypertensive management with first-line agents (ACE inhibitors, ARBs, calcium channel blockers, or thiazide diuretics).
Normotensive BPH Patients
Doxazosin can be safely used in normotensive men with BPH. Blood pressure reductions are clinically insignificant (approximately 4/2 mmHg) in this population 3, 5.
Pharmacologically Controlled Hypertensive Patients with BPH
Doxazosin may be added to existing antihypertensive regimens without causing clinically significant additional blood pressure reduction, though monitoring is required 5, 6.
Critical Safety Monitoring
Monitor blood pressure for at least 6 hours after:
- Initial dose
- Each dose increase 1
If therapy is discontinued for several days: Restart using the initial 1 mg dosing regimen 1
Primary adverse events to monitor:
- Orthostatic hypotension (most common)
- Dizziness
- Fatigue/asthenia
- Ejaculatory dysfunction
- Nasal congestion 2, 1
Combination Therapy Considerations
For BPH patients with large prostates, combination therapy with doxazosin plus a 5-alpha-reductase inhibitor (finasteride or dutasteride) is more effective than either agent alone in improving symptoms and reducing clinical progression 7, 8. The MTOPS trial demonstrated this combination significantly reduces risk of acute urinary retention and need for BPH-related surgery.
Do NOT combine doxazosin with low-dose daily tadalafil for BPH—this offers no symptom improvement advantage over either agent alone while increasing side effect risk 7.